SP
Therapeutic Areas
Alumis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Envudeucitinib | Moderate-to-Severe Plaque Psoriasis | Phase 3 |
Leadership Team at Alumis
MB
Martin Babler
President, Chief Executive Officer and Chairman of the Board
MB
Mark Bradley
Chief Development Officer
KB
Kolbot By, Ph.D.
SVP, Head of Technical Operations
JD
Jack Danilkowicz
Chief Commercial Officer
JD
Jörn Drappa M.D., Ph.D.
Chief Medical Officer
DM
David M Goldstein, Ph.D.
Chief Scientific Officer
GH
Grace Halteh
SVP, Head of Quality and Regulatory
RH
Roy Hardiman
Chief Business and Strategy Officer
CL
Claire Langrish, Ph.D.
SVP, Head of Immunology and Translational Science
JS
John Schroer
Chief Financial Officer